Dupilumab and prurigo nodularis-like phenotype in atopic dermatitis: our experience of efficacy

Ferrucci, Silvia; Tavecchio, Simona; Berti, Emilio; Angileri, Luisa

doi:10.1080/09546634.2019.1659479

Cited by 34 publications

(28 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Studies suggest the implication of the Th2 cytokine pathway [interleukin 4 (IL-4) and interleukin 13 (IL-13)] in its pathogenesis, 2 evidenced by recent monocentric case series showing the efficacy of IL-4 and IL-13 blocker (dupilumab) for PN treatment. [3][4][5][6][7][8] This study aimed to retrospectively determine the efficacy and safety of dupilumab treatment within a French multicentric cohort of 16 adult patients with chronic PN refractory to multimodal treatment regimens (April 2017-August 2019). Patients were classified as atopic (n = 7) and non-atopic PN (n = 9) as previously described.…”

mentioning

confidence: 99%

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

Călugăreanu

Jachiet

Tauber

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

The notion that it is related to M. lepromatosis may be true according to some authors. However, others showed that the correlation is not that strong, looking at leprosy clinical types in different countries 6 ; M. lepromatosis may resemble M. leprae in causing different manifestations depending on the host immunity. 2 From the group around Rea and Modlin, Maria Achoa reported at the World Congress Dermatology in Milano that of their Mexican patients with lepra bonita, the majority was indeed infected with M. lepromatosis, while some had a single M. leprae infection or a mixed infection. Whether M. lepromatosis affects the internal organs more than M. leprae is yet to be proven. The difference in the type of infection may in part account for clinical and geographical variabilities associated with leprosy infection; however, according to our opinion, the survival of the bacilli in the environment and the socioeconomic factors are relatively more important. For the practising dermatologist, the bacilli causing leprosy are of academic interest only. The treatment is the same, and it is the resistance to therapy that counts. As far as the role of physical medicine is concerned, she is right, but to direct this requires publishing of another article.

show abstract

mentioning

confidence: 99%

Effectiveness and safety of dupilumab for the treatment of prurigo nodularis in a French multicenter adult cohort of 16 patients

Călugăreanu

Jachiet

Tauber

et al. 2019

Acad Dermatol Venereol

View full text Add to dashboard Cite

show abstract

“…In the literature, some cases of PN were reported that were successfully treated with dupilumab, showing efficacy in reducing the itch (Beck, Yang, Sekhon, Bhutani, & Liao, ; Calugareanu et al, ; Ferrucci, Tavecchio, Berti, & Angileri, ; Mollanazar, Elgash, Weaver, et al, ; Napolitano et al, ; PH1 & JO2, ; Tanis, Ferenczi, & Payette, ; Zhai et al, ).…”

mentioning

confidence: 99%

Efficacy of dupilumab in prurigo nodularis in elderly patient

Giura

Viola

Fierro

et al. 2019

Dermatologic Therapy

View full text Add to dashboard Cite

Prurigo nodularis (PN) is a chronic disorder, affecting adults, with multiple nodules, typically on the limbs. The treatment is challenging, especially in elderly patients. An 85-year-old woman had developed in the last 3 years itch with nodular lesions and erythematous scaly patches and excoriations. The extension of the lesions was evaluated by body surface area (BSA) score and the patient's itch and disease-related sleep disorders by a Numeric Rating Scale (NRS) from 0 to 10. The Dermatology Life Quality Index (DLQI) and blood chemistry were performed before and during the therapy.At the baseline, the BSA score was 56%. Itch and disease-related sleep disorders

show abstract

“…Eine rezente Untersuchung zeigte eine gesteigerte [9]. Im Gegensatz zu unserer Patientin war das subjektive Ansprechen (Reduktion des Pruritus) in den meisten Fällen deutlich früher zu beobachten [10][11][12][13][14]. Nur wenige dieser Patienten zeigten ein langsameres Ansprechen auf die Behandlung mit Dupilumab.…”

Section: Clinical Letterunclassified